KR102087189B1 - Composition comprising Hibiscus syriacus L. extract for inhibiting antimicrobial peptides - Google Patents

Abstract

In the present specification, a composition for inhibiting antimicrobial peptides, which controls the expression level of antimicrobial peptide S100A7 (NM_002963) to a normal level, is disclosed as a composition comprising a rose of sharon as an active ingredient.
By using the composition for inhibiting the antimicrobial peptide, the expression level of the antimicrobial peptide increased by various causes can be returned to the normal level.

Description

Composition comprising Hibiscus syriacus L. extract for inhibiting antimicrobial peptides

Disclosed herein are compositions that inhibit antimicrobial peptides. More specifically, disclosed is a composition comprising a rose of sharon, which significantly changes the expression level of an antimicrobial peptide whose expression level is changed compared to normal skin cells due to various causes.

Antimicrobial peptides have recently attracted attention as substances that are similar in function to antibiotics and have been shown to be effective in boosting immunity.

Antimicrobial peptides are a type of immune defense system that has non-specificity against microbial invasion from outside of microorganisms, plants, insects, amphibians, and mammals. Structurally, it contains a large number of amino acids with a positive charge in the sequence, and exhibits a wide range of antimicrobial activities ranging from Gram positive groups, Gram negative bacteria and fungi, and cancer cells.

When these peptides bind to the cell membranes, they form ion channels in the cell membranes that inhibit the production of energy by the microorganisms, or create large pores in the cell membranes, resulting in cell death. As such, it is characterized by having a mechanism of action of destroying the cell membrane in a non-specific and effective physical method within a short time.

However, excessive antimicrobial peptides can have a rather detrimental effect. For example, it is well known that S100A7, a member of the S100 protein family, is an antimicrobial peptide. The exact mechanism is unknown, but damage to epidermal differentiation upon treatment with recombinant S100A7 peptide, and excessive presence of antimicrobial protein S100A7 in skin cells with atopic dermatitis (AD) and psoriasis lesions It is known to act as a negative regulator in epidermal differentiation (see Non-Patent Document 1).

Thus, there is a need to inhibit antimicrobial peptides in skin cells as a means to treat skin cell damage.

Son et al., "S100A7 (psoriasin) inhibits human epidermal differentiation by enhanced IL-6 secretionh through IκB / NF-κB signaling", Experimental Dermatology. 2016 Aug; 25 (8): 636-41. Kim, H.J., et al, "Transcriptome analysis of airborne PM2.5-induced detrimental effects on human keratinocytes", Toxicology Letters 273, 26-35, 2017.

In one aspect, the present invention is to provide an antimicrobial peptide inhibition composition.

In order to achieve the above object, in one aspect, the present invention provides a composition for inhibiting the antimicrobial peptides to control the expression level of the antimicrobial peptide S100A7 (NM_002963) to a normal level as a composition comprising the green light extract as an active ingredient. .

In one aspect, by using the composition for inhibiting the antimicrobial peptide provided by the present invention, the expression level of the antimicrobial peptide increased by various causes can be returned to the normal level.

Figure 1 shows the cell survival rate by the treatment of the fine dust extract, wherein ADSP represents yellow dust as Asian dust storm particles, PM10 (Particulate matter 10) fine dust having a particle size of 10㎛ PM2.5 (Particulate matter 2.5) indicates fine dust having a particle size of 2.5㎛.
Figure 2 shows that the mRNA expression level of the S100A7 gene in the skin cells stimulated by PM2.5 fine dust increased, and returned to normal levels by the Mugunghwa extract treatment.

Hereinafter, the present invention will be described in detail.

In one aspect of the present invention, the antimicrobial peptide inhibition composition may include a rose of sharon as an active ingredient.

Mugunghwa ( Hibiscus syriacus L. ) belongs to the deciduous shrub of the dicotyledonous mallow. Its height is 3-4m, and young branches have hairs but gradually disappear. Mugunghwa is easy to cultivate in the garden and can be reproduced with seeds, but it is easy to maintain without altering the traits because it is propagated by the pit. The leaves are alternate, egg-shaped, usually divided into three, and the edge is serrated. The outer skin of Mugunghwa is peeled off and used as a raw material for paper. Young leaves are edible and flowers and leaves can be drunk as tea.

Rose of Sharon is an antioxidant and has the main ingredient of Saponarin with expectorant effect. The roots and bark of Mugunghwa are known to contain tannic acid, flowers and leaves are saponariin, and species and stalks include Malvalic acid and Sterculic acid.

Dongbobom and herbaceous bark are used for painful and hemorrhoidal pain by applying or steaming the roots and skins with moon or concern, and drying the flowers and leaves and taking them with hot water, which is effective for expectoration, thirst quenching, vomiting and restoring appetite. In addition, the bell is recorded smoked burned the affected area can be used as a headache, migraine control, treatment for thickening. Other benefits include: relieving blood loss, antipyretic, detoxification, swelling of cotton, induction of gynecological diseases, scabies, analgesic and antifungal effects, prevention of hair growth and hair loss, bronchitis, influenza, enteritis, dysentery, antidepressants, Insecticidal effects.

In the past, Mugunghwa used leaves that were cooked as old crops. Mugunghwa petals make rice cakes and tea. Young Mugunghwa leaves are used to make herbs and miso soup. In Europe and China, leaves and flowers are used as herbal teas, and buds cooked as court spice are used. In addition, fiber is obtained from the bark of Mugunghwa and used as a refining fee.

In one aspect, the composition of the present invention may use the leaves, stems, shells, roots, fruits, flowers or buds, seeds and the like of Rose of Sharon. Specifically, the composition of the present invention may use extracts such as leaves, stems, bark, roots, fruits, flowers or buds, and seeds of rose of sharon, in one embodiment, the composition of the present invention is a rosewood bark extract ( Hibiscus syriacus BARK EXTRACT).

In one aspect of the present invention, the rose of sharon can be extracted with a specific extraction solvent to form the rose of sharon.

In one aspect of the present invention, the Rose of Sharon extract may be prepared by extracting Rose of Sharon with water or an organic solvent. Specifically, the green light is extracted with any one or more selected from the group consisting of water, C ₁ -C ₆ anhydrous or hydrous lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane It can be prepared by extraction with a solvent.

In one aspect, the Rose of Sharon extract may be extracted at room temperature.

In one aspect, the green light extract may be obtained by additionally undergoing one or more of evaporation, filtration, concentration, separation or drying after the extraction with the extractant. In particular, the Mugunghwa extract may be subjected to one or more filtration processes, in one embodiment two filtration processes.

In one embodiment, the separation process may include a centrifugation process.

Specifically, the extraction comprises water, a polar solvent comprising C ₁ -C ₆ anhydrous or hydrous lower alcohol, acetone and butylene glycol and ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane One or more of the low polar solvents may be used as the solvent.

More specifically, the solvent may be 50-90% aqueous ethanol solution, 60-80% or 65-75% aqueous ethanol solution. When the solvent is 50-90% ethanol aqueous solution, it is possible to effectively extract the active ingredient in Mugunghwa. In one embodiment, the solvent may be about 70% aqueous ethanol solution.

In one aspect, the extract may be concentrated under reduced pressure to an appropriate temperature in a distillation apparatus equipped with a cooling condenser after extraction.

However, the rose of sharon according to the present invention can be obtained by extracting by a conventional method in the art, it is not limited by the above-described method.

In one aspect of the present invention, in the composition, the composition may include the green light extract, 0.000001 to 30% by weight based on the total weight of the composition. When the content is 0.000001 to 30% by weight, the skin damage caused by the fine dust by the rose of sharon extract was excellent.

Specifically, at least 0.0000001 wt%, at least 0.0000005 wt%, at least 0.0000007 wt%, at least 0.0000009 wt%, at least 0.000001 wt%, at least 0.000002 wt%, at least 0.000004 wt%, at least 0.000006 wt%, at least 0.000008 wt%, at least 0.00001 wt% At least 0.00003 wt%, at least 0.00005 wt%, at least 0.00007 wt%, at least 0.00009 wt%, at least 0.0001 wt%, at least 0.0003 wt%, at least 0.0005 wt%, at least 0.0007 wt%, at least 0.0009 wt%, 0.001 wt% Or more, 0.01 or more, 0.1 or more, 0.1 or more, 1 or more, 3 or more, 5 or more, 5 or more, 7 or more, 9 or more, 10 or more, 13 or more, 15 or more May be at least%, at least 17 wt%, at least 19 wt%, at least 21 wt%, at least 23 wt%, at least 25 wt%, at least 27 wt%, at least 29 wt%, at least 30 wt%, at least 31 wt%, 32 wt% or less, 31 wt% or less, 30 wt% or less, 29 wt% or less, 28 wt% or less, 26 wt% or less, 24 wt% % Or less, 22% or less, 20% or less, 18% or less, 16% or less, 14% or less, 12% or less, 10% or less, 9% or less, 8% or less, 6% or less % Or less, 4% or less, 2% or less, 1% or less, 0.1% or less, 0.09% or less, 0.04% or less, 0.01% or less, 0.006% or less, 0.001% or less, 0.0009 weight or less % Or less, 0.0007% or less, 0.00005% or less, 0.00003% or less, 0.00001% or less, 0.000009% or less, 0.000007% or less, 0.000005% or less, 0.000003% or less, 0.000001% or less, 0.0000009 weight or less % Or less, 0.0000007 wt% or less, 0.0000005 wt% or less, 0.0000003 wt% or less, 0.0000002 wt% or less, 0.0000001 wt% or less, 0.00000009 wt% or less, but is not limited thereto.

Another aspect of the invention includes the use of the antimicrobial peptide inhibition of the composition.

As used herein, the term "fine dust" refers to a substance having a particle diameter of 10 μm or less, which is a small substance which is invisible to our eyes and floats or scatters in the air for a long time. Particularly, particulate matter having a particle diameter of 2.5 μm or less is referred to as "ultrafine dust", and in the present invention, "fine dust" is intended to include "ultrafine dust".

In one aspect, the present invention provides a composition that inhibits the antimicrobial peptide by controlling the expression level of a specific gene in skin cells to a normal level.

Specifically, the expression level of the antimicrobial peptide S100A7 (NM_002963) may be affected by various causes in the present invention, and when the expression level of the antimicrobial peptide S100A7 (NM_002963) is increased by such a cause, using the composition Antimicrobial peptides can be inhibited by inhibiting the expression levels of these genes and adjusting to normal levels.

As used in the present invention, the gene whose expression level is increased by various causes is shown in Table 1. [Table 1] shows genes that are antimicrobial peptides with increased expression. In these tables, Name means genebank accession ID of NCBI, Gene Symbol means official gene symbol, and Gene title indicates the name of each gene. it means. This content can be confirmed through description of Nonpatent literature 2.

Increase gene Name Gene
Symbol Gene title NM_002963 S100A7 S100 calcium binding protein A7

Expression analysis of the gene or protein is microarray, PCR, NGS (Nest Generation Sequencing), Western blot, Northern blot, ELISA, radioimmunoassay, radioimmunoassay, tissue immunostaining, immunoprecipitation assay, etc. It can be analyzed using various analytical methods known in the art.

In one aspect of the present invention, the composition may be a cosmetic composition, may be a pharmaceutical composition, may be a dietary supplement composition.

The cosmetic composition includes, for example, cosmetics such as various creams, lotions, various creams, lotions, skins, and the like, cleansing agents, face washes, soaps, and essences.

In one aspect, the cosmetic composition is added to the composition containing the green light extract of the present invention may take the form of solutions, emulsions, viscous mixtures and the like.

That is, in one aspect, the cosmetic of the present invention is not particularly limited in the formulation, for example, latex, cream, lotion, essence, pack, gel, powder, makeup base, foundation, lotion, ointment, patch, essence, cleansing Formulations such as foams, cleansing creams, cleansing water, body lotions, body creams, body oils, body essences, shampoos, rinses, body cleansers, soaps, hair dyes, sprays and the like.

In the cosmetic composition of each formulation, the other components in addition to the extract of Mugunghwa can be appropriately selected and blended by those skilled in the art without difficulty according to the formulation or use purpose of other cosmetics.

In addition, in one aspect the cosmetic of the present invention may comprise a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids and seaweed extract.

In one aspect, you may mix | blend the cosmetics of this invention with the said essential component and the other component normally mix | blended with a cosmetics as needed.

Other components that may be added include fats and oils, humectants, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, flavorings, Blood circulation accelerators, cooling agents, restriction agents, purified water and the like.

In addition, the compounding component which may be added other than this is not limited to this, Moreover, any of the above components can also be mix | blended within the range which does not impair the objective and effect of this invention.

In one aspect, the pharmaceutical composition comprising the green light extract of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.

As the dosage form, the pharmaceutical composition comprising the extract of Mugunghwa can be used as an oral preparation such as tablets, capsules, powders or syrups, or external preparations such as ointments, gels, creams, patches or sprays according to a conventional method. It may be formulated into any form suitable for pharmaceutical preparations.

In general, it should be understood that the actual dosage of the active ingredient administered by the pharmaceutical composition should be determined in view of several related factors such as the severity of the symptom, the route of administration chosen, the age, sex, weight and health of the subject. In general, the dosage of the active ingredient may be from 0.0001 mg / kg / day to 3000 mg / kg / day, for example 10 mg / kg / day to 500 mg / kg / day.

In the health functional food composition, which is one aspect of the present invention, the health food is manufactured using nutrients or ingredients (functional ingredients) having useful functions to the human body, which are easily deficient in daily meals, and maintain the normal functioning of the human body. Or it may mean a food to maintain and improve the health through physiological function, but is not limited thereto. The health food may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, and the like, but is not limited thereto and may be manufactured and processed in any form according to the law.

Specifically, the health beverage composition is not particularly limited to other ingredients except for containing the compound as essential ingredients in the indicated ratios, and may contain various flavors or natural carbohydrates, etc. as additional ingredients, such as ordinary drinks. Examples of natural carbohydrates are conventional sugars such as monosaccharide polysaccharides, cyclodextrins, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.

In general, it should be understood that the actual dosage of the active ingredient administered by the dietary supplement composition should be determined in view of several related factors such as the severity of the symptom, the route of administration chosen, the age, sex, weight and health of the subject. . In general, the dosage of the active ingredient may be 0.0001 mg / kg / day to 1000 mg / kg / day, for example, 0.02 mg / kg / day to 6 mg / kg / day.

Hereinafter, the configuration and effects of the present invention will be described in more detail with reference to Examples. However, these examples are provided only for the purpose of illustration to help the understanding of the present invention is not limited to the scope and scope of the present invention by the following examples.

Example 1 Preparation of Rose of Sharon Extract

Mugunghwa ( Hibiscus syriacus ) was cultivated in Gyeongsangbuk-do, and obtained from Moacam. The bark of the obtained rose of sharon was extracted with a solvent extracted from a mixture of purified water and ethanol at a ratio of 3: 7, that is, 70% ethanol at room temperature, and the alcohol was evaporated. After the extraction at room temperature, the primary filtration was removed to remove the solid material contained in the extract, and then the extract was concentrated to remove ethanol and then separated and purified. And dried after centrifugation and secondary filtration to obtain a rose of sharon.

Example 2 Fine Dust Collection and Extraction

The fine dust was collected using a low volume air sampler (Sensidyne, Gillian, Low Volume Air Sampler, FL, USA), and the filter pack was replaced by a filter and a denude at around 10 am every measurement day for about 24 hours. Was taken. For 28 days, fine dust was collected every day at Poongha Station (Seoul, Yongin-si, Gyeonggi-do, 6th floor of Korean Studies University Foreign Studies Center), and the measurement time was controlled by turning on the vacuum pump and turning off the vacuum pump. The time was recorded. The sampling flow rate was 16.7 L / min, and the flow rate was measured using a flow meter (Model 4143, TSI Inc.) at the start of the measurement, and the flow rate was measured again at the end of the measurement. The Teflon filter in the filter pack was weighed before and after sampling. Before weighing the Teflon filter, weigh it in a desiccator (NIKKO, Japan) with a relative humidity of 40% for 24 hours, and then weigh twice on an electronic scale (DVG215CD, Ohaus) with 5 decimal places. Recorded. Even after the sample was taken, the weight was measured in a desiccator for 24 hours before weighing, and then the weight was measured twice and compared with the weight measured before sampling to calculate the mass concentration. Extraction of fine dust was performed by soaking the Teflon filter in 1 mL of ethanol and then adding 14 mL of DW so that the aerosol trapping surface of the filter was in contact with the water, and then applying ultrasonic waves for 30 minutes with an ultrasonic cleaner. In order to minimize the error caused by the water in the filtration step, the filter is completely removed from the filter for 48 hours and then weighed using a ultra-precision scale (Mettler Toledo Company) that can measure up to 0.1 mg. The weights were weighed before and after extraction of the filter.

Example 3 Culture of (normal human) keratinocyte line

Human normal epidermal keratinocytes were purchased from Lonza, Inc., Walkersville, MD, and passaged under 37 ° C and 5% CO2 conditions in a CO2 incubator. Incubated. Cell cultures were in accordance with Ronza's guidelines. KGM-2 Bullet Kit, CC-4152 (Component: Bovine pituitary extract), human epidermal growth, in 500 ml of KBM-2 (CCM-3, CC-3103) medium Human epidermal growth factor (hEGF), insulin, Insulin, Hydrocortisone, transferrin, epinephrine, and gentamycin sulfate + amphotericin-B (Gentamycin Suflate + Amphofericin-B: GA KGM-2 bullet kit CC-3107 (KGMTM-2 Bullet Kit, CC-3107) was used.

Example 4 Treatment of Fine Dust and Measurement of Cytotoxicity in (Normal Human) Keratinocytes

In order to confirm the cytotoxicity through the fine dust treatment, MTT experiment using a (normal human) keratinocyte cell line was performed by the method of Mossman et al. (J. Immunol. Methods, 65, 55-63, 1983).

Specifically, a fine dust dispersion was prepared by using a 24-well plate and dispersing fine dust having a diameter of 2.5 μm obtained in Example 3 in purified water, and then 2.5 × 10 ⁵ under the cell culture conditions of Example 4 Cells cultured in the well cell condition were treated with the fine dust dispersion and cultured for 24 hours, followed by mixing 5 mg / ml of MTT (3-4,5-dimethylthiazol-2,5-diphenyltetra zolium bromide) 37 Further incubation for 3 hours at ℃. Thereafter, the medium was removed, and the formed formazan crystal was dissolved in 500 µl of DMSO. The lysate was transferred to a 96-well plate and aliquoted and the OD value was measured at absorbance 540 nm. The measurement result is shown in FIG.

As shown in FIG. 1, the concentration (IC20) value of 80% survival rate against the cytotoxicity caused by the dispersion in which the fine dust was dispersed at 2.5 micrometers or less in the cell line was 12.5 µg / Ml.

Example 5 Confirmation of Cell Gene Changes in Fine Dust Through Next Generation Sequencing

For RNA-sequence data processing and analysis, reference was made to general analysis steps developed by Trapnell et al. (2012). RNA-seq data quality was confirmed using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and FASTX (http://hannonlab.cshl.edu/fastx_toolkit/) This eliminated inferior base and adapter sequences. The alignment was then performed using Tophat (Trapnell et al., 2009) and the human genome (hg19), and the amount of data in each sample was confirmed using EVER-seq, renamed RSeQC (Wang et al., 2012). ). In addition, expression levels of transcripts were quantified using Cufflinks, and transcription levels were compared between microdust dispersion treated samples and normal samples (Trapnell et al., 2010). By applying a strict cutoff of ≧ 2.0 fold-change with a FDR adjusted p-value <0.05, genes having significant expression differences in the treatment of dispersions of fine dust with a diameter of 2.5 μm were determined. The measurement results are shown in the following [Table 2] and [FIG. 2].

Increase gene Name Gene
Symbol Multiple change NM_002963 S100A7 23.8

Example 6 Real-Time RT-PCR Quantitation

The fine dust having a diameter of 2.5 μm extracted in Example 2 was treated in human cultured keratinous skin cells cultured in Example 3 in an amount of 12.5 μg in 1 ml of the cell culture medium, and the applied biosystems of genes shown in Table 3 below. TaqMan® Primers) were used to determine relative mRNA expression levels. The green light extract used was prepared in Example 1.

Increase gene Name Gene
Symbol TaqMan® Primer NM_002963 S100A7 Hs00161488_m1

After 24 hours of treatment with Mugunghwa extract in a medium at a concentration of 20 ppm, the culture medium was removed, the cells were washed with 2 ml of Phosphate Buffered Saline (PBS), and then trizol reagent (Trizol reagent, Invitrogen, Carlsbad) was used. , CA, USA) was used to isolate RNA in cells. The isolated RNA was purified once more with KIAGEN's RNA kit (QIAGEN RNeasy kt, QIAGEN, Valencia, Calif.), Followed by Agilent's BioAnalyzer 2100 model instrument (Agilent 2100 BioAnalyzer, Agilent Technologies, Santa Clara, CA, USA). ) Was used to confirm the quality of RNA. CDNA was synthesized from the RNA using Invitrogen's reverse transcriptase kit (Superscript Reverse Transcriptase (RT) kit, Invitrogen, Carlsbad, CA), and the real-time reverse transcription polymerase chain reaction using the primers of [Table 3] (Q) -RT-PCR: Quantitative analysis was performed by real time-reverse transcription polymerase chain reaction. Changes in the expression patterns of the genes were evaluated by real-time PCR using the Applied Biosystem's TaqMan gene expression assay kit (TaqMan gene expression assay kit, Applied Biosystems, Foster City, CA). Shown in Both Q-RT-PCR and real-time PCR used were performed according to the standard protocol distributed by Life Technology. Specifically, after 20 seconds at 95 ° C., 3 seconds at 95 ° C. and 30 seconds at 60 ° C. were performed. 40 cycles were carried out.

As shown in FIG. 2, a gene having an increased expression level in skin cells stimulated by fine dust exists, and the expression level of the S100 calcium binding protein A7 (S100A7) gene was reduced by the treatment of the rose of sharon. .

Thus, it can be seen that the extract of Mugunghwa effectively protects skin cells from stimulation by an antimicrobial peptide, and inhibits or prevents the expression level of a specific gene from being changed by the stimulus, thereby allowing a normal level of expression. have.

Hereinafter, the formulation example of the composition according to the present invention, but the cosmetic composition, pharmaceutical composition and nutraceutical composition is applicable to various formulations, which is intended to explain in detail only and not intended to limit the present invention. .

 Formulation Example 1 Tablet

100 mg of the green light extract, 400 mg of lactose, 400 mg of corn starch, and 2 mg of magnesium stearate were mixed and compressed into tablets according to a conventional method for preparing tablets.

Ingredient Content (mg) Rose of Sharon Extract 100 Lactose 400 Corn starch 400 Magnesium Stearate 2

Formulation Example 2 Capsule

The capsules were prepared by mixing 100 mg of green light extract according to the embodiment of the present invention, 400 mg of lactose, 400 mg of corn starch, and 2 mg of magnesium stearate, and then filling the gelatin capsules according to a conventional method for preparing capsules.

Ingredient Content (mg) Rose of Sharon Extract 100 Lactose 400 Corn starch 400 Magnesium Stearate 2

Formulation Example 3 Granules

50 mg of the green light extract according to the embodiment of the present invention, 250 mg of anhydrous glucose and 550 mg of starch were mixed and molded into granules by using a fluidized bed granulator, and then filled into fabrics.

Ingredient Content (mg) Rose of Sharon Extract 50 Anhydrous glucose 250 Starch 550

Formulation Example 4 Soap

Ingredient content(%) Rose of Sharon Extract 5.00 maintain Quantity Sodium hydroxide Quantity Sodium chloride Quantity Spices Quantity Purified water Remaining amount

[Formulation Example 5] Lotion

Ingredient content(%) Rose of Sharon Extract 5.00 L-ascorbic acid-2-phosphate magnesium salt 1.00 Soluble collagen (1% aqueous solution) 1.00 Sodium citrate 0.10 Citric acid 0.05 Licorice Extract 0.20 1,3-butylene glycol 3.00 Purified water Remaining amount

Formulation Example 6 Cream

Ingredient content(%) Rose of Sharon Extract 3.00 Polyethylene Glycol Monostearate 2.00 Self-emulsifying glycerin monostearate 5.00 Cetyl alcohol 4.00 Squalene 6.00 Glyceryl tri2-ethylhexanoate 6.00 Sphingolipid 1.00 1.3-butylene glycol 7.00 Purified water Remaining amount

Formulation Example 7 Ointment

Ingredient content(%) Rose of Sharon Extract 5.00 Polyvinyl alcohol 13.00 L-ascorbic acid-2-phosphate magnesium salt 1.00 Lauroylhydroxyproline 1.00 Soluble collagen (1% aqueous solution) 2.00 1,3-butylene glycol 3.00 ethanol 5.00 Purified water Remaining amount

 Formulation Example 8 Preparation of Serum

Ingredient content(%) Rose of Sharon Extract 3.00 Hydroxyethylene Cellulose (2% aqueous solution) 12.00 Xanthan gum (2% aqueous solution) 2.00 1,3-butylene glycol 6.00 Dark glycerin 4.00 Sodium hyaluronate (1% aqueous solution) 2.00 Purified water Remaining amount

Formulation Example 9 Health Food

Compounding ingredients content Rose of Sharon Extract 2mg Vitamin A Acetate 70 μg Vitamin E 1.0mg Vitamin B1 0.13mg Vitamin B2 0.15mg Vitamin B6 0.5mg Vitamin B12 0.2 μg Vitamin c 10mg Biotin 10 μg Nicotinic acid amide 1.7mg Folic acid 50 μg Calcium Pantothenate 0.5mg Ferrous sulfate 1.75mg Zinc oxide 0.82 mg Magnesium carbonate 25.3 mg Potassium phosphate monobasic 15 mg Dicalcium Phosphate 55 mg Potassium citrate 90 mg Calcium carbonate 100 mg Magnesium chloride 24.8 mg

Formulation Example 10 Health Drink

Ingredient content Rose of Sharon Extract 50 mg Citric acid 1000 mg oligosaccharide 100 g Taurine 1 g Purified water Remaining amount

Claims (10)

As an antimicrobial peptide inhibition composition,
Water, or a Mugunghwa extract extracted with anhydrous or hydrous lower alcohol of C ₁ -C ₆ as an active ingredient, the antimicrobial peptide comprises S100A7 (NM_002963), antimicrobial peptide composition for inhibition. The method of claim 1,
The Rose of Sharon extract is contained in an amount of 0.000001 to 30% by weight based on the total weight of the composition. delete The method of claim 1,
The Rose of Sharon extract is extracted from the bark of Rose of Sharon, the composition. delete The method of claim 1,
The composition is applied to keratinocytes. The method of claim 1,
Wherein the green light extract is administered at a dosage of 10 to 500 mg / kg / day. The method of claim 1,
The composition is a cosmetic composition. delete The method of claim 1,
Wherein said composition is a nutraceutical composition.

Images